* Based on sensor features including up to 15-day wear period, automatic readings every minute, accuracy data, and single-app setup with AID systems.
† Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and FreeStyle Libre 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
‡ Based on patient applied FDA cleared iCGMs replacing blood glucose testing for diabetes treatment decisions.
§ Based on the same glucose algorithm between FreeStyle Libre 2 and FreeStyle Libre 3 family of sensors.
II Multicenter study evaluating sensor data from FreeStyle Libre 3 and Dexcom G7 compared to blood plasma glucose under real world conditions. Study limitations: Study subjects followed their daily routines and were not exposed to risks of hyperglycemia or hypoglycemia manipulations, neither sensor was evaluated for accuracy during times of rapidly changing glucose. Outcome measures: Differences in mean absolute relative difference, number and percentage of matched glucose pairs within ±20 mg/dL/±20% of reference values. Results from 55 subjects (minimum required sample size: 42). Registration in clinicaltrials.gov is not required as the study does not meet the definition of Applicable Clinical Trial. Study funding provided by Abbott.
¶ FreeStyle Libre 2 and 3 systems are cleared to be used by children 4 years and older with Libre 2 and 3 sensors and 2 years and older with Libre 2 and 3 Plus sensor.
** Based on retail and DME sales data for patient’s last-filled prescription, by manufacturer.
References: 1. Haak, T. Diabetes Therapy (2017): https://doi.org/10.1007/s13300-016-0223-6. 2. Alva, S. Diabetes Therapy (2023): https://doi.org/10.1007/s13300-023-01385-6. 3. Dexcom G6 and Dexcom G7 User Guides. 4. Hanson, K. Journal of Diabetes Science and Technology (2024): https://doi.org/10.1177/19322968231225676. 5. Data on file. Abbott Diabetes Care. 6. FreeStyle Libre 2 User’s Manual and FreeStyle Libre 3 User’s Manual.